Key result
Adipose tissue dynamically drives multi-organ fibrotic remodeling through depot- and stage-specific immunometabolic mechanisms.
Why the study?
Adipose tissue influences fibrotic remodeling across multiple organs through complex mechanisms that require synthesis and unification for therapeutic targeting.
Adipose tissue acts as a dynamic endocrine organ that can both promote and inhibit multi-organ fibrosis, offering emerging therapeutic targets such as adiponectin signaling and adipose browning.
Adipose tissue is a dynamic endocrine and immunometabolic organ that shapes fibrotic remodeling within and beyond its anatomical boundaries. This review synthesizes evidence across skin, heart, liver and intestine to articulate a unifying adipose-fibrotic axis. We highlight depot- and stage-specific mechanisms, including adipokine signaling, adipocyte-to-myofibroblast transition, disordered lipid metabolism, and microbiome-mesenteric fat interactions, and distill convergent pathways. We further propose a stage-dependent model in which early lipolysis can be protective whereas sustained lipolysis promotes fibrosis, yielding testable therapeutic windows. Finally, we map a transitional landscape spanning cellular (ADSCs/exosomes), metabolic (browning/thermogenesis) and microbiome-directed strategies, and we outline outstanding questions for clinical translation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a review in Multi-organ fibrosis. Adipose-fibrotic axis modulation was evaluated. Adipose tissue acts as a dynamic endocrine and immunometabolic organ that shapes fibrotic remodeling across multiple organs through depot- and stage-specific mechanisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: